Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EC0905
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Oral, Intravenous, Intradermal, Subcutaneous, Intramuscular, Intraperitoneal, Intrathecal
01
Overview
EC0905 is a *folic acid–desacetylvinblastine hydrazide (DAVLBH) conjugate* designed as a targeted cytotoxic agent for cancer treatment. The drug connects folic acid to DAVLBH via a cleavable disulfide-containing hydrophobic linker. This configuration enables the compound to selectively bind to folate receptor-alpha (FRα)-positive cancer cells, leading to receptor-mediated endocytosis. Once internalized, the reducing environment within the endosome cleaves the linker, releasing DAVLBH, a potent microtubule inhibitor, to induce cytotoxicity. The conjugate’s design is intended to maximize anti-tumor efficacy while limiting toxicity to non-target cells. EC0905 is similar in design concept to vintafolide (EC145), a related folate-targeted vinca alkaloid conjugate.
02
Targets
FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on EC0905.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EC0905.